A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
NCT07726160
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Relapse and/or Refractory Multiple Myeloma
Interventions
BIOLOGICAL:
KIV-318
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
[object Object]